Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

Inclusion Criteria: * Men or women with age \> 35 and ≤ 65 years; * Subjects seeking tissue augmentation treatment on the face; * Subjects willing to receive HA Filler for one and/or more mimetic and/or superficial facial wrinkles located in the facial area including periocular area; * Subjects willing to receive HA Filler for one and/or more mimetic and/or superficial facial wrinkles; * Subjects willing to provide signed informed consent to clinical investigation participation. Exclusion Criteria: * Use of aspirin and antiplatelet agents a week prior to treatment; * Pregnant or lactating women; * Subjects with a history of allergy or hypersensitivity to the HA or to other ingredients of the dermal filler; * Subjects with hypersensitivity to salicylic acid or any of its derivates; * Subjects with any dermal systemic pathologies, such as systemic lupus erythematosus, psoriasis, scleroderma etc.; * Subjects presenting bleeding disorders in the past or present; * Subjects taking or having indications for anticoagulant therapy; * Use of concomitant treatments or procedures aimed to improve skin rejuvenation over the last six months before the clinical investigation enrolment, such as chemical peeling, dermabrasion, laser resurfacing; * Subjects suffering from infectious diseases including herpes simplex virus infection, active hepatitis or human immunodeficiency virus; * Subjects suffering from eczema, acne, and keloids; * Subjects with any cutaneous manifested infection, disease or alteration; * Subjects at risk in term of precautions, warnings, and contra-indications referred in the package insert of the clinical investigation device; * Subjects with any facial aesthetic surgery in the preceding 12 months before the clinical investigation enrolment; * Subjects with any active irritation or inflammation in the target areas of injection; * Subjects who received botulinum toxin A injections in the face in the preceding 6 months; * Subjects unlikely to cooperate in the clinical investigation or to comply with the treatment or with the clinical investigation visits; * Subjects with solar activity, such as prolonged exposure to the sun, UV rays and extreme conditions of heat for at least a week after the treatment * Direct or indirect contact with quaternary ammonium salts during the investigation * Subjects participating in another clinical investigation or treated with another HA filler with the same indications at the same time or within the preceding 30 days.